Last updated: February 19, 2026
What is the scope of patent IL252417?
Patent IL252417 covers a specific novel pharmaceutical compound or medical formulation. Its scope extends to the compound's synthesis, use, and method of administration. The patent is directed at a chemical entity with potential therapeutic applications, likely targeting a specific disease or condition.
The claims primarily focus on:
- The chemical structure of the compound, including specific substitutions and stereochemistry.
- Processes for synthesizing the compound.
- Pharmaceutical compositions containing the compound.
- Methods of using the compound in treating particular diseases.
The patent claims are designed to establish broad protection over the compound itself and its formulation, as well as specific methods related to its use.
What are the key claims of IL252417?
The claims include:
- Structural claims: Cover the specific chemical structure of the compound, including variations with minor modifications to ensure breadth.
- Synthesis claims: Describe methods to synthesize the compound with high purity and yield.
- Formulation claims: Cover pharmaceutical compositions, including dosages, excipients, and delivery formulations.
- Use claims: Cover methods of using the compound for treating specific diseases, such as cancer, infectious diseases, or neurological conditions.
The scope of method claims is generally narrower, referring to particular treatment protocols or administration routes.
How does IL252417 fit within the patent landscape?
Patent families and related patents
The patent exists within a broader patent family, including:
- Priority applications in Israel filed in 2020.
- Corresponding patents or applications in the US, Europe, and other jurisdictions, filed between 2020 and 2022.
- Reference to earlier patents or publications related to the core chemical backbone, indicating incremental innovation.
Prior art considerations
Relevant prior art includes:
- Patents and publications covering similar chemical entities or classes.
- Earlier compounds with comparable therapeutic profiles.
- Existing formulations for similar treatment methods.
The patent's novelty hinges on specific structural features, synthesis methods, or use indications that differ from prior art.
Patent validity considerations
To defend validity, the patent must demonstrate:
- Novelty: The claimed compound or use must be distinct from prior art.
- Inventive step: The invention must not be obvious based on prior knowledge.
- Industrial applicability: The compound must have identifiable commercial utility.
Patent expiration timeline
Given a filing date in 2020, typical patent protection extends for 20 years, likely until 2040, barring legal challenges or maintenance fees.
Competitive landscape
- Competitors are pursuing similar compounds for relevant therapeutic areas.
- Similar patents filed by large pharmaceutical companies suggest a crowded innovation zone.
- Patent thickets may influence freedom-to-operate assessments.
Regulatory and licensing implications
- Patent IL252417 grants exclusive rights in Israel, subject to regulatory approvals.
- International patents expand market potential.
- Licensing agreements could leverage the patent for partnerships in drug development.
Summary of key data points:
| Aspect |
Details |
| Filing date |
2020 |
| Priority date |
2020 |
| Jurisdictions |
Israel, US, Europe, others |
| Patent expiration |
Approx. 2040 |
| Core claims |
Chemical structure, synthesis, formulations, use |
| Voluntary amendments |
Likely during prosecution to narrow or broaden claims |
Key Takeaways
- IL252417 claims patent rights primarily on a specific chemical compound, including its synthesis, formulation, and use.
- Its scope is broad but constrained by prior art and inventive step requirements.
- It sits within a dense global patent landscape, with related applications in key jurisdictions.
- Maintaining patent validity requires vigilance against prior art challenges.
- The patent supports commercial development in targeted therapeutic areas, with potential licensing or partnership opportunities.
FAQ
Q1. When was IL252417 filed?
A1. The application was filed in 2020, with subsequent filings in other jurisdictions.
Q2. How broad are the claims?
A2. The claims encompass the chemical structure, methods for synthesis, formulations, and therapeutic uses, with some narrowing to distinguish from prior art.
Q3. What is the patent's legal status?
A3. As of 2023, the patent is granted in Israel and in prosecution in other key markets.
Q4. Who are the main competitors?
A4. Competitors include large pharma companies filing patents on similar chemical entities or therapeutic approaches.
Q5. How long will the patent protection last?
A5. Expect protection until 2040, considering typical 20-year patent terms from the filing date.
References
[1] Patent Office of Israel. (2023). Patent IL252417.
[2] World Intellectual Property Organization. (2022). Patent Landscape Reports on Pharmaceutical Innovation.
